Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.36 |
| ▸ | MAOB | P27338 | 5/20 | 0.34 |
| ▸ | MAOA | P21397 | 4/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260479 | 0.75 | MAPT (0.38) | GRM2MAOBMAOAPGRKDM4E | |
| SCHEMBL259949 | 0.74 | PARP1 (0.39) | GRM2MAOBMAOAPGRHTR2A | |
| SCHEMBL260488 | 0.71 | MAPT (0.49) | PGRALDH1A1SMN1; SMN2TP53MAPT | |
| SCHEMBL259729 | 0.71 | AHR (0.45) | MAOBPGRHTR2APDE4B | |
| SCHEMBL6964280 | 0.63 | PDE4B (0.54) | PDE4B | |
| SCHEMBL259969 | 0.58 | LMNA (0.46) | PGRALDH1A1SMN1; SMN2TP53MAPT | |
| SCHEMBL27145518 | 0.57 | CCR2 (0.42) | ALDH1A1MAPT | |
| SCHEMBL27965958 | 0.56 | CASP3 (0.42) | HTR2AKDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL260681 | 0.56 | LMNA (0.63) | PGRALDH1A1SMN1; SMN2TP53MAPT | |
| SCHEMBL2085735 | 0.55 | LMNA (0.63) | PGRALDH1A1SMN1; SMN2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653073-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2014-02-18 | — | — | US | disclosed |
| US-20130331380-A1 | DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2013-12-12 | — | — | US | disclosed |
| US-8541412-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2013-09-24 | — | — | US | disclosed |
| EP-2281822-B1 | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2013-01-16 | — | — | EP | disclosed |
| US-20120046287-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-02-23 | — | — | US | disclosed |
| EP-2281822-A1 | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2011-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331380-A1 | DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CYP11B1, SDHA, CYP11B2 | GRM2 3255/4885MAOB 1216/4885MAOA 1788/4885 |
| US-20120046287-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | CYP11B1, SDHA, CYP11B2 | GRM2 3255/4885MAOB 1216/4885MAOA 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.